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Abstract 
Review on ADRB2, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: ADRB2R, ADRBR, B2AR, BAR, 
BETA2AR 
HGNC (Hugo): ADRB2 
Location: 5q32 
DNA/RNA 
Description 
ADBR2 gene spans about 2,04 kb and consists of 
one exon. 
Transcription 
ADBR2 no has introns in either their coding or 
untranslated sequences. The primary transcripts are 
processed at their 5' and 3' ends like other 
premessenger RNAs, but no splicing is needed. 
Pseudogene 
No pseudogenes have been reported. 
Protein 
Description 
β2 adrenergic receptor is a member of the 
superfamily of G-protein coupled receptors 
(GPCRs) (McGraw and Liggett, 2005; Johnson,  
2006). The receptor is comprised of 413 amino acid 
residues of approximately 46500 daltons (Johnson, 
2006). β2 adrenergic receptor is N-glycosylated at 
amino acids 6, 15, and 187; these are important for 
roper insertion of the receptor into the membrane as 
well as for agonist trafficking (McGraw and 
Liggett, 2005; Johnson, 2006). 
Expression 
β2 adrenergic receptor is widely distributed, this 
protein is expressed by airway smooth muscle (30-
40000 per cell), epithelial and endothelial cells of 
the lung, smooth muscle of blood vessels, skeletal 
muscle, mast cells, lymphocytes, oral and skin 
keratinocytes and also by diverse cancer cells 
(Kohm and Sanders, 2001; Lutgendorf et al., 2003; 
Johnson, 2006; Sood et al., 2006; Thaker et al., 
2006; Yang et al., 2006; Sastry et al., 2007; Yu et 
al., 2007; Liu et al., 2008a; Liu et al., 2008b; Shang 
et al., 2009; Sivamani et al., 2009; Yang et al., 
2009; Bernabé et al., 2011; Bravo-Calderón et al., 
2011-2012; Steenhuis et al., 2011; Zhang et al., 
2011; Loenneke et al., 2012). 
Localisation 
β2 adrenergic receptor is a transmembrane protein. 
Like all GPCRs, the β2 adrenergic receptor has 
seven transmembrane a domains that form a pocket 
containing binding sites for agonists and 
competitive antagonists (McGraw and Liggett, 
2005; Johnson, 2006). There are 3 extracellular 
loops, with one being the amino terminus, and 3 
intracellular loops, with a carboxy terminus 
(McGraw and Liggett, 2005; Johnson, 2006). 
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Activation of protein kinase A (PKA) by signal transduction of β2 adrenergic receptor (adapted of Rosenbaum et al., 2009). 
 
Function 
Agonist binding of β2 adrenergic receptor results in 
activation of Gs protein. The Gs protein a subunit 
stimulates adenylyl cyclase to generate cyclic 3'-5'-
adenosine monophosphate (cAMP), which in 
sequence activates the cAMP-dependent protein 
kinase A (PKA) and the agonist-occupied receptor 
is phosphorylated.  
After phosphorylation, the receptor switches its 
coupling specificity to Gi. GTP-bound Giα 
dissociates from the heterodimeric Gβγ, and free 
Gβγ subunits mediate activation of the MAP kinase 
signaling pathway in the same way as Gi-coupled 
receptors. Increase of intracellular cAMP levels 
leads diverse cell functions as cell proliferation, 
differentiation, angiogenesis and migration (Daaka 
et al., 1997). 
Implicated in 
Ovarian carcinoma 
Note 
Reverse transcriptase-PCR studies indicated 
constitutive expression of β2 adrenergic receptor on 
ovarian carcinoma cell lines (Lutgendorf et al., 
2003). Lutgendorf et al. (Lutgendorf et al., 2003) 
investigated the effects of norepinephrine and 
isoproterenol (a nonspecific-adrenergic agonist) on 
the production of vascular endothelial growth factor 
(VEGF) by ovarian cancer cell lines; and found that 
both, norepinephrine and isoproterenol, 
significantly enhanced VEGF production. These 
effects were blocked by thenon-specific β 
antagonist propranolol, supporting a role 
foradrenergic receptors in these experimental 
effects.  
Norepinephrine was later found to increase the in 
vitro invasive potential of ovarian cancer cells, an 
effect that was blocked by propranolol (Sood et al., 
2006). Norepinephrine also increased tumor cell 
expression of matrix metalloproteinase-2 (MMP-2) 
and MMP-9, and pharmacologic blockade of 
MMPs abrogated the effects of norepinephrine on 
tumor cell invasive potential (Sood et al., 2006).  
In the same way, Thaker et al. (Thaker et al., 2006) 
correlated chronic behavioral stress with higher 
levels of tissue catecholamines and more invasive 
growth of ovarian carcinoma cells in an orthotopic 
mouse model. These effects were mediated through 
β2 adrenergic receptor activation of PKA signaling 
pathway (Thaker et al., 2006). Tumors in stressed 
animals showed increased vascularization and 
enhanced expression of VEGF, MMP2 and MMP9; 
these effects could be abrogated by propranolol 
(Thaker et al., 2006). 
Prostate cancer 
Note 
β2 adrenergic receptor signaling was related to 
prostate cancer cell progression (Sastry et al., 2007; 
Zhang et al., 2011). β2 adrenergic receptor 
activation of PKA signaling pathway has been 
associated with reduction of sensitivity of prostate 
cancer cells to apoptosis (Sastry et al., 2007) and 
promotion of cell proliferation and cell migration 
(Zhang at al., 2011).  
Contrastingly, other investigation demonstrated that 
the genetic silencing of β2 adrenergic receptor 
increases cell migration and invasion of normal 
ADRB2 (adrenoceptor beta 2, surface) Oliveira DT, Bravo-Calderón DM 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(9) 661 
prostate cells and that the weak expression of this 
protein is associated with metastases and with worst 
survival rates in prostate cancer patients (Yu et al., 
2007). 
Esophageal squamous cell 
carcinoma 
Note 
Liu et al. (Liu et al., 2008b) demonstrated that 
stimulation of β2 adrenergic receptor with 
epinephrine significantly increase the esophageal 
cancer cell proliferation accompanied by elevation 
of the expression of VEGF, VEGF receptor 
VEGFR-1 and VEGFR-2. In addition, it has been 
shown that the epidermal growth factor mediates 
the mitogenic signals in esophageal cancer cells 
through transactivation of β2 adrenergic receptor 
(Liu et al., 2008a). 
Oral squamous cell carcinoma 
(OSCC) 
Note 
Genetic and protein expression of β2 adrenergic 
receptor was demonstrated in OSCC by using RT-
PCR assay, Western blot and 
immunohistochemistry (Shang et al., 2009; Bernabé 
et al., 2011; Bravo-Calderón et al., 2011-2012). 
Investigations performed in different oral cancer 
cell lines demonstrated that β2 adrenergic receptor 
signaling by norepinephrine increases cell 
proliferation and invasion, and upregulates 
interleukin-6 (IL-6) gene expression and protein 
release (Shang et al., 2009; Bernabé et al., 2011). 
Furthermore, Shang et al. (Shang et al., 2009) 
reported that malignant cell positive 
immunoexpression of β2-AR was significantly 
correlated with age, tumor size, clinical stage and 
cervical lymph node metastasis in OSCC patients, 
and that β2-AR may play an important role in the 
formation and metastasis of oral cancer. However, a 
retrospective clinical study of a large number of 
patients showed that patients with OSCC who 
exhibited strong β2-AR immunohistochemical 
expression by malignant epithelial cells 
demonstrated higher survival rates compared to 
patients with weak/negative β2-AR expression 
(Bravo-Calderón et al., 2011-2012). Therefore, 
further clinical and laboratory studies are warranted 
to elucidate the role of β2 adrenergic receptor 
activation in oral squamous cell carcinoma. 
Various cancers 
Note 
β2 adrenergic receptor was also 
immunohistochemically identified in 
nasopharyngeal carcinoma (Yang et al., 2006) and 
in melanoma (Yang et al., 2009). Norepinephrine 
treatment increased MMP-2, MMP-9, and VEGF 
levels in culture supernatants of nasopharyngeal 
carcinoma cells lines (Yang et al., 2006); as well 
upregulated the production of VEGF, interleukin 
(IL)-8, and IL-6 in human melanoma tumor cell 
lines (Yang et al., 2009). 
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